P50 CA 69568/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
1997	1
1998	4
1999	1
2000	3
2001	2
2002	5
2003	4
2004	3
2005	1
2006	4
2007	5
2008	3
2024	0

1

Pilat MJ, Kamradt JM, Pienta KJ. Pilat MJ, et al. Cancer Metastasis Rev. 1998-1999;17(4):373-81. doi: 10.1023/a:1006166511344. Cancer Metastasis Rev. 1998. PMID: 10453281 Free article. Review. No abstract available.

2

Differential proteomic alterations between localised and metastatic prostate cancer.

Taylor BS, Varambally S, Chinnaiyan AM. Taylor BS, et al. Br J Cancer. 2006 Aug 21;95(4):425-30. doi: 10.1038/sj.bjc.6603274. Epub 2006 Aug 1. Br J Cancer. 2006. PMID: 16880794 Free PMC article. Review.

3

The role of alpha(v)beta(3) in prostate cancer progression.

Cooper CR, Chay CH, Pienta KJ. Cooper CR, et al. Neoplasia. 2002 May-Jun;4(3):191-4. doi: 10.1038/sj.neo.7900224. Neoplasia. 2002. PMID: 11988838 Free PMC article. Review.

4

Stromal factors involved in prostate carcinoma metastasis to bone.

Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichman RS, McCauley LK, Keller ET, Pienta KJ. Cooper CR, et al. Cancer. 2003 Feb 1;97(3 Suppl):739-47. doi: 10.1002/cncr.11181. Cancer. 2003. PMID: 12548571 Free article. Review.

5

Cancer cells homing to bone: the significance of chemotaxis and cell adhesion.

Cooper CR, Sikes RA, Nicholson BE, Sun YX, Pienta KJ, Taichman RS. Cooper CR, et al. Cancer Treat Res. 2004;118:291-309. doi: 10.1007/978-1-4419-9129-4_12. Cancer Treat Res. 2004. PMID: 15043197 Review. No abstract available.

6

Decreased galectin-3 expression in prostate cancer.

Pacis RA, Pilat MJ, Pienta KJ, Wojno K, Raz A, Hogan V, Cooper CR. Pacis RA, et al. Prostate. 2000 Jul 1;44(2):118-23. doi: 10.1002/1097-0045(20000701)44:2<118::aid-pros4>3.0.co;2-u. Prostate. 2000. PMID: 10881021 Free article.

7

Antimetastatic drugs in prostate cancer.

Chay CH, Cooper CC, Hellerstedt BA, Pienta KJ. Chay CH, et al. Clin Prostate Cancer. 2002 Jun;1(1):14-9. doi: 10.3816/cgc.2002.n.002. Clin Prostate Cancer. 2002. PMID: 15046708 Review.

8

Synthesis and structure-activity investigation of iodinated arylhydantoins and arylthiohydantoins for development as androgen receptor radioligands.

Van Dort ME, Jung YW. Van Dort ME, et al. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5285-8. doi: 10.1016/j.bmcl.2004.08.031. Bioorg Med Chem Lett. 2004. PMID: 15454212

9

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, Chinnaiyan AM. Tomlins SA, et al. Cancer Res. 2006 Apr 1;66(7):3396-400. doi: 10.1158/0008-5472.CAN-06-0168. Cancer Res. 2006. PMID: 16585160

10

CCR2 expression correlates with prostate cancer progression.

Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, Zhang J. Lu Y, et al. J Cell Biochem. 2007 Jun 1;101(3):676-85. doi: 10.1002/jcb.21220. J Cell Biochem. 2007. PMID: 17216598 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year